Newton: Transports ...
Health Care: Drugs
Sangamo BioSciences Inc. (SGMO: NASDAQ)
$4.42 -0.36 | -7.53%
02/09/12 - 12:08 PM ET
198.59K / 335.20K
Vol / Avg. Vol:4.83 / 4.78
Open / Prev. Close:4.40 - 4.83
Today's Range:2.36 - 9.15
52 Wk Range:68.31%
Performance YTD:TheStreet Rating:
Portfolios with SGMO
- Portfolio NameUser Type
- UserStock Game
- Contributor10 Biotech Trades for Secon...
- UserEnergy and Biotech
- UserPART 6 JPMorgan 28th Annual...
- Userpj's stocks
- UserWilliam T Blanchard - Medical
- UserPART 2 JPMorgan 27th Annual...
- ProHeartland Value - HRTVX
- Userdarthvader23 Portfolio 1
- UserFerrengi Holdings
Latest SGMO Headlines from TheStreet
- Sangamo BioSciences' CEO Discusses Q4 2011 Results - Earnings Call Transcript 02.08.12 | 10:02 pm
- Sangamo BioSciences' CEO Presents At The 30th Annual J.P. Morgan Healthcare Conference (Transcript) 01.12.12 | 03:01 pm
- Sangamo BioSciences At Lazard Capital Markets 8th Annual Healthcare Conference Call Transcript 11.15.11 | 02:11 pm
- Sangamo BioSciences' CEO Discusses Special Call Transcript 10.03.11 | 11:10 am
- Sangamo's Management Discusses Phase 2b Clinical Trial SB-509-901 Top Line Data - Conference Call Transcript 10.03.11 | 11:10 am
- Sangamo BioSciences Stock Gaps Down On Today's Open (SGMO) 10.03.11 | 09:10 am
- Sangamo Nerve Regrowth Drug Fails Key Test 10.03.11 | 08:10 am
- Biotech Stock Mailbag: Medivation, Targacept 09.23.11 | 05:09 am
- Sangamo Gene Therapy Fights HIV 09.19.11 | 07:09 am
- The Next Big Thing in Biotech: Sangamo
09.18.11 | 11:09 am
Press Releases for SGMO
- Sangamo BioSciences Announces Fourth Quarter And Full Year 2011 Conference Call And Webcast - PR Newswire 02.01.12 | 04:02 pm
- Shire And Sangamo Collaborate To Develop Therapeutics For The Treatment Of Hemophilia And Other Monogenic Diseases - PR Newswire 02.01.12 | 07:02 am
- Shire And Sangamo Collaborate To Develop Therapeutics For The Treatment Of Hemophilia And Other Monogenic Diseases - PR Newswire 02.01.12 | 07:02 am
- Sangamo BioSciences Announces Initiation Of Two New Phase 2 HIV Clinical Trials - PR Newswire 01.09.12 | 07:01 am
- Sangamo BioSciences Announces Presentation At J.P. Morgan Healthcare Conference - PR Newswire 01.05.12 | 04:01 pm
- Sangamo BioSciences Announces Presentation Of New Data From ZFP Therapeutic® Program In Hemophilia B At American Society For Hematology Meeting - PR Newswire 12.13.11 | 07:12 am
- Sangamo BioSciences Announces Presentation At The Lazard Capital Markets 8th Annual Healthcare Conference - PR Newswire 11.08.11 | 04:11 pm
- Sangamo BioSciences Announces Third Quarter 2011 Conference Call And Webcast - PR Newswire 10.18.11 | 04:10 pm
- Sangamo BioSciences Announces Presentation At The 18th Annual Newsmakers In The Biotech Industry Conference - PR Newswire 10.14.11 | 04:10 pm
- Sangamo BioSciences Announces Publication In Nature Of Gene Correction Strategy For Alpha 1-Antitrypsin Deficiency - PR Newswire 10.13.11 | 07:10 am
Partner Headlines for SGMO
- Stocks Choppy; U.S. Manufacturing Data Show Modest Gains, Greece Weighs - NASDAQ 10.03.11 | 04:10 pm
- Mid-Day Update: Stocks Fall as Greece Concerns Outweigh Economic Uptick - NASDAQ 10.03.11 | 04:10 pm
- Sangamo's Phase II Results To Be Announced Monday - Expect Good News - Seeking Alpha 10.02.11 | 07:10 am
- Sangamo BioSciences to Host Conference Call to Discuss Results From Phase 2b Diabetic Neuropathy Trial Monday 8:30am - Benzinga 09.30.11 | 06:09 pm
- Sangamo gene therapy shows promise in reducing HIV - Reuters 09.18.11 | 01:09 pm
- Sangamo Biosciences's Game Changing Technology - Seeking Alpha 04.20.11 | 08:04 am
- Squeeze Ideas: 17 Short Seller Targets for a Watchlist - Seeking Alpha 04.01.11 | 06:04 pm
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- Sangamo HIV drug shown to boost immune cell counts - Reuters 02.28.11 | 08:02 am
